6598 Stock Overview
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Applied BioCode Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$19.75 |
| 52 Week High | NT$28.40 |
| 52 Week Low | NT$20.05 |
| Beta | 0.52 |
| 1 Month Change | -7.71% |
| 3 Month Change | -13.76% |
| 1 Year Change | -29.21% |
| 3 Year Change | -55.27% |
| 5 Year Change | -54.90% |
| Change since IPO | -71.58% |
Recent News & Updates
Shareholder Returns
| 6598 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -6.0% | -2.1% | -2.1% |
| 1Y | -29.2% | 2.0% | 27.5% |
Return vs Industry: 6598 underperformed the TW Medical Equipment industry which returned 2% over the past year.
Return vs Market: 6598 underperformed the TW Market which returned 27.5% over the past year.
Price Volatility
| 6598 volatility | |
|---|---|
| 6598 Average Weekly Movement | 2.5% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6598 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6598's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Winston Z. Ho | www.apbiocode.com |
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. The company’s products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. It develops assays, such as BioCode SARS-CoV-2 Assay, a nucleic acid assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; and CoV-2 Flu Assay for detection of RNA and various Influenza, as well as offers gastrointestinal and respiratory pathogen panel related products.
Applied BioCode Corporation Fundamentals Summary
| 6598 fundamental statistics | |
|---|---|
| Market cap | NT$1.66b |
| Earnings (TTM) | -NT$164.20m |
| Revenue (TTM) | NT$395.17m |
4.1x
P/S Ratio-9.8x
P/E RatioIs 6598 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6598 income statement (TTM) | |
|---|---|
| Revenue | NT$395.17m |
| Cost of Revenue | NT$126.43m |
| Gross Profit | NT$268.74m |
| Other Expenses | NT$432.94m |
| Earnings | -NT$164.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.01 |
| Gross Margin | 68.01% |
| Net Profit Margin | -41.55% |
| Debt/Equity Ratio | 0% |
How did 6598 perform over the long term?
See historical performance and comparison